​

AnaptysBio (ANAB) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

ANAB Stock Forecast

AnaptysBio stock forecast is as follows: an average price target of $49.83 (represents a 211.63% upside from ANAB’s last price of $15.99) and a rating consensus of 'Buy', based on 11 wall street analysts offering a 1-year stock forecast.

ANAB Price Target

The average price target for AnaptysBio (ANAB) is $49.83 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $90.00 to $19.00. This represents a potential 211.63% upside from ANAB's last price of $15.99.

ANAB Analyst Ratings

Buy

According to 11 Wall Street analysts, AnaptysBio's rating consensus is 'Buy'. The analyst rating breakdown for ANAB stock is 0 'Strong Buy' (0.00%), 6 'Buy' (54.55%), 5 'Hold' (45.45%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

AnaptysBio Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 11, 2024Emily BodnarH.C. Wainwright$19.00$15.5122.50%18.82%
Nov 06, 2024Emily BodnarH.C. Wainwright$52.00$19.38168.32%225.20%
Nov 06, 2024David RisingerLeerink Partners$45.00$19.38132.20%181.43%
Oct 21, 2024Yatin SunejaGuggenheim$90.00$34.98157.29%462.85%
Oct 15, 2024Yasmeen RahimiPiper Sandler$80.00$34.74130.28%400.31%
Oct 03, 2024David RisingerNew Street$35.00$35.22-0.62%118.89%
Aug 15, 2024Joon LeeTruist Financial$30.00$34.65-13.42%87.62%
Apr 16, 2024David RisingerLeerink Partners$47.00$21.27120.97%193.93%
Nov 18, 2022J.P. Morgan$32.00$29.169.74%100.13%

The latest AnaptysBio stock forecast, released on Dec 11, 2024 by Emily Bodnar from H.C. Wainwright, set a price target of $19.00, which represents a 22.50% increase from the stock price at the time of the forecast ($15.51), and a 18.82% increase from ANAB last price ($15.99).

AnaptysBio Price Target by Period

1M3M12M
# Anlaysts168
Avg Price Target$19.00$53.50$49.75
Last Closing Price$15.99$15.99$15.99
Upside/Downside18.82%234.58%211.13%

In the current month, the average price target of AnaptysBio stock is $19.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 18.82% increase as opposed to AnaptysBio's last price of $15.99. This month's average price target is down -64.49% compared to last quarter, and down -61.81% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Dec 11, 2024H.C. WainwrightBuyNeutralDowngrade
Dec 02, 2024BTIGNeutralDowngrade
Oct 30, 2024H.C. WainwrightBuyBuyHold
Oct 21, 2024WedbushBuyBuyHold
Oct 21, 2024GuggenheimBuyBuyHold
Oct 15, 2024Piper SandlerOverweightOverweightHold
Oct 03, 2024Leerink PartnersOutperformOutperformHold
Sep 26, 2024WedbushBuyBuyHold
Aug 06, 2024WedbushBuyBuyHold
Aug 06, 2024Cowen & Co.BuyBuyHold
Aug 06, 2024WedbushOutperformOutperformHold
May 10, 2024Wells FargoBuyBuyHold
Mar 12, 2024WedbushNeutralOutperformUpgrade
Jan 06, 2023Raymond JamesOutperformMarket PerformDowngrade
Nov 01, 2022Credit SuisseNeutralDowngrade
Nov 01, 2022Wells FargoUnderweightDowngrade
Nov 01, 2022Piper SandlerNeutralDowngrade
Nov 01, 2022GuggenheimBuyUpgrade
Nov 01, 2022Craig-HallumHoldDowngrade
Sep 02, 2022Raymond JamesOutperformInitialise
Apr 26, 2022WedbushNeutralNeutralHold

AnaptysBio's last stock rating was published by H.C. Wainwright on Dec 11, 2024. The company Downgrade its ANAB rating from "Buy" to "Neutral".

AnaptysBio Financial Forecast

AnaptysBio Revenue Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
Revenue-----------------$3.32M$3.46M$1.37M$6.81M$1.29M$1.22M$970.00K$1.01M$20.89M$30.03M$11.25M$60.00M-
Avg Forecast$10.00M$10.00M$10.00M$10.00M$10.00M$10.00M$10.00M$10.00M$9.05M$9.72M$8.02M$7.82M$7.79M$8.21M$22.76M$4.00M$3.79M$2.29M$2.68M$2.90M$5.78M$13.43M$5.30M$5.05M$976.00K$6.65M$28.88M$9.39M$80.00M$2.00M
High Forecast$18.75M$18.75M$18.75M$18.75M$18.75M$18.75M$18.75M$18.75M$16.96M$18.22M$15.03M$14.66M$17.31M$15.38M$22.76M$4.00M$4.04M$2.31M$5.03M$5.43M$10.84M$13.43M$5.30M$5.05M$976.00K$6.65M$28.88M$9.39M$80.00M$2.00M
Low Forecast$6.56M$6.56M$6.56M$6.56M$6.56M$6.56M$6.56M$6.56M$5.94M$6.38M$5.26M$5.13M$1.73M$5.38M$22.76M$4.00M$3.46M$2.26M$1.76M$1.90M$3.80M$13.43M$5.30M$5.05M$976.00K$6.65M$28.88M$9.39M$80.00M$2.00M
# Analysts633333454527842242221111222222
Surprise %-----------------1.45%1.29%0.47%1.18%0.10%0.23%0.19%1.04%3.14%1.04%1.20%0.75%-

AnaptysBio's average Quarter revenue forecast for Dec 23 based on 4 analysts is $3.79M, with a low forecast of $3.46M, and a high forecast of $4.04M. ANAB's average Quarter revenue forecast represents a 14.09% increase compared to the company's last Quarter revenue of $3.32M (Sep 23).

AnaptysBio EBITDA Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts633333454527842242221111222222
EBITDA-----------------$-37.73M$-40.14M$-39.92M$-22.14M$-26.78M$-26.11M$-30.83M$-33.60M$-6.00M$482.00K$-18.04M$33.79M$-23.63M
Avg Forecast$-8.28M$-8.28M$-8.28M$-8.28M$-8.28M$-8.28M$-8.28M$-8.28M$-7.49M$-8.05M$-6.64M$-6.48M$-6.45M$-6.79M$-18.84M$-18.24M$-3.13M$-1.89M$-2.22M$-19.51M$-4.79M$-11.14M$-4.40M$-20.86M$-810.12K$-5.52M$-23.97M$-18.82M$-66.40M$-1.66M
High Forecast$-5.43M$-5.43M$-5.43M$-5.43M$-5.43M$-5.43M$-5.43M$-5.43M$-4.92M$-5.28M$-4.36M$-4.25M$-1.43M$-4.46M$-18.84M$-14.59M$-2.87M$-1.87M$-1.46M$-15.61M$-3.14M$-11.14M$-4.40M$-16.69M$-810.12K$-5.52M$-23.97M$-15.06M$-66.40M$-1.66M
Low Forecast$-15.53M$-15.53M$-15.53M$-15.53M$-15.53M$-15.53M$-15.53M$-15.53M$-14.05M$-15.09M$-12.44M$-12.14M$-14.34M$-12.74M$-18.84M$-21.89M$-3.34M$-1.92M$-4.17M$-23.41M$-8.98M$-11.14M$-4.40M$-25.04M$-810.12K$-5.52M$-23.97M$-22.59M$-66.40M$-1.66M
Surprise %-----------------19.91%18.06%2.05%4.62%2.40%5.94%1.48%41.48%1.09%-0.02%0.96%-0.51%14.23%

2 analysts predict ANAB's average Quarter EBITDA for Sep 21 to be $-5.52M, with a high of $-5.52M and a low of $-5.52M. This is -1245.91% lower than AnaptysBio's previous annual EBITDA (Jun 21) of $482.00K.

AnaptysBio Net Income Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts633333454527842242221111222222
Net Income-----------------$-37.31M$-39.84M$-48.45M$-26.41M$-37.37M$-37.31M$-40.76M$-31.09M$-6.67M$-429.00K$-18.16M$33.65M$-23.77M
Avg Forecast$-34.09M$-31.65M$-29.71M$-29.21M$-49.35M$-46.15M$-44.84M$-43.98M$-38.94M$-39.81M$-39.33M$-39.62M$-46.78M$-47.58M$-30.07M$-21.45M$-46.25M$-51.34M$-48.99M$-22.94M$35.76M$-17.02M$-26.86M$-24.54M$-27.08M$-23.26M$-2.81M$-18.95M$53.14M$-19.74M
High Forecast$-18.86M$-17.51M$-16.43M$-16.15M$-27.30M$-25.53M$-24.80M$-24.33M$-21.54M$-22.02M$-21.75M$-27.16M$-36.09M$-26.32M$-16.63M$-17.16M$-40.93M$-28.40M$-27.09M$-18.35M$42.91M$-17.02M$-26.86M$-19.63M$-27.08M$-23.26M$-2.81M$-15.16M$53.14M$-19.74M
Low Forecast$-72.88M$-67.66M$-63.50M$-62.43M$-105.48M$-98.64M$-95.85M$-94.01M$-83.24M$-85.09M$-84.06M$-50.09M$-53.13M$-101.71M$-64.28M$-25.74M$-55.29M$-109.75M$-104.71M$-27.53M$28.61M$-17.02M$-26.86M$-29.44M$-27.08M$-23.26M$-2.81M$-22.74M$53.14M$-19.74M
Surprise %-----------------0.73%0.81%2.11%-0.74%2.20%1.39%1.66%1.15%0.29%0.15%0.96%0.63%1.20%

AnaptysBio's average Quarter net income forecast for Mar 21 is $-18.95M, with a range of $-22.74M to $-15.16M. ANAB's average Quarter net income forecast represents a -156.33% decrease compared to the company's last Quarter net income of $33.65M (Dec 20).

AnaptysBio SG&A Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts633333454527842242221111222222
SG&A-----------------$10.17M$10.68M$10.82M$9.41M$8.86M$8.17M$10.20M$5.39M$5.43M$5.25M$5.42M$5.09M$4.79M
Avg Forecast$17.22M$17.22M$17.22M$17.22M$17.22M$17.22M$17.22M$17.22M$15.58M$16.74M$13.80M$13.47M$13.41M$14.13M$39.19M$6.89M$6.52M$3.94M$4.62M$4.99M$5.41M$23.12M$9.12M$8.70M$1.68M$11.46M$49.74M$5.66M$137.76M$3.44M
High Forecast$32.29M$32.29M$32.29M$32.29M$32.29M$32.29M$32.29M$32.29M$29.21M$31.38M$25.88M$25.25M$29.81M$26.49M$39.19M$6.89M$6.96M$3.99M$8.67M$9.35M$6.49M$23.12M$9.12M$8.70M$1.68M$11.46M$49.74M$6.79M$137.76M$3.44M
Low Forecast$11.30M$11.30M$11.30M$11.30M$11.30M$11.30M$11.30M$11.30M$10.22M$10.98M$9.06M$8.84M$2.98M$9.27M$39.19M$6.89M$5.96M$3.90M$3.03M$3.27M$4.33M$23.12M$9.12M$8.70M$1.68M$11.46M$49.74M$4.53M$137.76M$3.44M
Surprise %-----------------2.58%2.31%2.17%1.74%0.38%0.90%1.17%3.21%0.47%0.11%0.96%0.04%1.39%

AnaptysBio's average Quarter SG&A projection for Dec 23 is $6.52M, based on 4 Wall Street analysts, with a range of $5.96M to $6.96M. The forecast indicates a -35.92% fall compared to ANAB last annual SG&A of $10.17M (Sep 23).

AnaptysBio EPS Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts633333454527842242221111222222
EPS-----------------$-1.41$-1.50$-1.73$-0.93$-1.32$-1.32$-1.47$-1.13$-0.24$-0.02$-0.66$1.23$-0.87
Avg Forecast$-1.18$-1.10$-1.03$-1.01$-1.71$-1.60$-1.55$-1.52$-1.35$-1.38$-1.36$-1.37$-1.62$-1.65$-1.04$-1.57$-1.60$-1.78$-1.70$-1.03$-0.96$-0.62$-0.98$-0.99$-0.99$-0.85$-0.10$-0.69$1.94$-0.72
High Forecast$-0.65$-0.61$-0.57$-0.56$-0.94$-0.88$-0.86$-0.84$-0.75$-0.76$-0.75$-0.94$-1.25$-0.91$-0.58$-0.87$-1.42$-0.98$-0.94$-0.57$-0.53$-0.62$-0.98$-0.99$-0.99$-0.85$-0.10$-0.69$1.94$-0.72
Low Forecast$-2.52$-2.34$-2.20$-2.16$-3.65$-3.41$-3.32$-3.25$-2.88$-2.94$-2.91$-1.73$-1.84$-3.52$-2.22$-3.35$-1.91$-3.80$-3.62$-2.21$-2.05$-0.62$-0.98$-0.99$-0.99$-0.85$-0.10$-0.69$1.94$-0.72
Surprise %-----------------0.79%0.88%1.68%0.97%2.12%1.34%1.48%1.14%0.28%0.19%0.96%0.63%1.21%

According to 2 Wall Street analysts, AnaptysBio's projected average Quarter EPS for Mar 21 is $-0.69, with a low estimate of $-0.69 and a high estimate of $-0.69. This represents a -155.96% decrease compared to ANAB previous annual EPS of $1.23 (Dec 20).

AnaptysBio Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
ANABAnaptysBio$15.99$49.83211.63%Buy
CTMXCytomX Therapeutics$1.13$3.47207.08%Buy
KURAKura Oncology$9.74$23.33139.53%Buy
CRNXCrinetics Pharmaceuticals$55.37$69.0024.62%Buy
RYTMRhythm Pharmaceuticals$56.80$64.5013.56%Buy

ANAB Forecast FAQ

Is AnaptysBio a good buy?

Yes, according to 11 Wall Street analysts, AnaptysBio (ANAB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 54.55% of ANAB's total ratings.

What is ANAB's price target?

AnaptysBio (ANAB) average price target is $49.83 with a range of $19 to $90, implying a 211.63% from its last price of $15.99. The data is based on 11 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will AnaptysBio stock go up soon?

According to Wall Street analysts' prediction for ANAB stock, the company can go up by 211.63% (from the last price of $15.99 to the average price target of $49.83), up by 462.85% based on the highest stock price target, and up by 18.82% based on the lowest stock price target.

Can AnaptysBio stock reach $20?

ANAB's average twelve months analyst stock price target of $49.83 supports the claim that AnaptysBio can reach $20 in the near future.

What is AnaptysBio's current price target trend?

1 Wall Street analyst forecast a $19 price target for AnaptysBio (ANAB) this month, up 18.82% from its last price of $15.99. Compared to the last 3 and 12 months, the average price target increased by 234.58% and increased by 211.13%, respectively.

What are AnaptysBio's analysts' financial forecasts?

AnaptysBio's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $40M (high $75M, low $26.25M), average EBITDA is $-33.121M (high $-21.735M, low $-62.101M), average net income is $-184M (high $-102M, low $-394M), average SG&A $68.88M (high $129.15M, low $45.2M), and average EPS is $-6.379 (high $-3.529, low $-13.636). ANAB's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $40M (high $75M, low $26.25M), average EBITDA is $-33.121M (high $-21.735M, low $-62.101M), average net income is $-125M (high $-68.952M, low $-266M), average SG&A $68.88M (high $129.15M, low $45.2M), and average EPS is $-4.314 (high $-2.386, low $-9.222).

Did the ANAB's actual financial results beat the analysts' financial forecasts?

Based on AnaptysBio's last annual report (Dec 2022), the company's revenue was $10.29M, which missed the average analysts forecast of $29.56M by -65.20%. Apple's EBITDA was $-108M, beating the average prediction of $-41.193M by 161.19%. The company's net income was $-129M, beating the average estimation of $-32.657M by 294.16%. Apple's SG&A was $36.64M, missing the average forecast of $46.35M by -20.95%. Lastly, the company's EPS was $-4.57, beating the average prediction of $-3.556 by 28.52%. In terms of the last quarterly report (Sep 2023), AnaptysBio's revenue was $3.32M, beating the average analysts' forecast of $2.29M by 44.98%. The company's EBITDA was $-37.732M, beating the average prediction of $-1.895M by 1891.22%. AnaptysBio's net income was $-37.308M, missing the average estimation of $-51.344M by -27.34%. The company's SG&A was $10.17M, beating the average forecast of $3.94M by 158.11%. Lastly, the company's EPS was $-1.41, missing the average prediction of $-1.777 by -20.65%